Case Report

Isolated Kaposi Sarcoma of the Tonsil: A Case Report and Review of the Scientific Literature

Barbara Pittore,1 Carlo Loris Pelagatti,1 Francesco Deiana,1 Francesco Ortu,2 Elena Maricosu,3 Sergio Cossu,3 and Giovanni Sotgiu4

1 Otorhinolaryngology Department, S. Francesco Hospital, ASL 3, Nuoro, Italy
2 Immunology Department, AOU Cagliari, Italy
3 Pathology Department, S. Francesco Hospital, ASL 3, Nuoro, Italy
4 Epidemiology and Medical Statistics Unit, Medical Education and Professional Development Unit, Department of Biomedical Sciences, University of Sassari-Research, AOU Sassari, Italy

Correspondence should be addressed to Barbara Pittore; barbarapitt@tiscali.it

Received 4 December 2014; Accepted 20 January 2015

Academic Editor: Manish Gupta

Copyright © 2015 Barbara Pittore et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Kaposi sarcoma is a tumour caused by human herpes virus 8, also known as Kaposi sarcoma-associated herpes virus. It usually affects the skin and oral mucosa; however, it can also sometimes affect the lungs, liver, stomach, bowel, and lymph nodes. Several body sites may be affected simultaneously. The involvement of the tonsils is rare. We described an isolated localization of Kaposi’s sarcoma of the right tonsil in a HIV-positive patient.

1. Introduction

HIV/AIDS represents an important clinical and public health issue worldwide. The estimated HIV/AIDS prevalence in 2012 was 35,300,000 worldwide in 2012 (WHO. Global report: UNAIDS report on the global AIDS epidemic 2013, UNAIDS/JC2502/I/E.). In case of severe immunodeficiency, the probability of occurrence of several opportunistic disorders (e.g., infections and tumours) can increase. Kaposi's sarcoma (KS) is a frequently reported neoplasia in HIV-positives; it is caused by human herpes virus 8 (HHV-8), also known as KS-associated herpes virus (KSHV) [1]. The most recurrently affected sites are the skin and mucous membrane [2, 3]; however, it can be found in other parts of the body (i.e., lungs [4], stomach [5], intestine [6], etc.). The KS of the head and neck usually involves the mucous membranes of the oral cavity [7], but it can be found in the pharynx [8, 9], larynx [10], and nose [11]. Isolated oropharyngeal location, in particular the tonsils one, is extremely rare [12–16].

Here, we present a case of KS of the right tonsil in a HIV-positive patient, surgically treated and exposed to antiretroviral drugs.

2. Case Report

A 42-year-old man was admitted to the Emergency Department of the S. Francesco Hospital, Nuoro, Italy, because of a painless swelling, moderate bleeding, located in his right tonsil. He referred to its occurrence without any other relevant symptoms 1 month ahead.

Oral examination shows a purple swelling (Figure 1) in the upper pole of his right tonsil, sized about 1.5 cm (maximum diameter). Further clinical examinations did not detect any other lesions in the head and neck district. The suspected diagnosis was a pyogenic granuloma. The patients did not reveal his known HIV positivity. He underwent a tonsillectomy with complete excision of the above mentioned tumour.

The histopathological analysis identified a KS (Figures 2, 3, 4, and 5). In order to better understand the etiology and the staging of the tumour a diagnostic plan was arranged: HIV-testing, endoscopy of the upper part of the digestive tract, and computer tomography scanning of the chest and abdomen.

His past medical history includes a borderline hypertension treated with a diet approach.
Table 1: TIS classification [17].

| TIS classification | Good category | Clinical categories | Poor category |
|--------------------|---------------|---------------------|--------------|
| T                  | Skin, lymfonode, mucosa of the mouth | Oedema and ulceration, KS of the mouth, KS of the gastrointestinal tract, KS of the viscera |
| I                  | CD4 cells count ≥ 200 cells/μL | CD4 cells count 200 cells/μL |
| S                  | No history of opportunistic disease; no fever, loss of weight, persistent diarrhea | Disease as lymphoma, neurological disease, fever, and so forth |

After surgical treatment his CD4 lymphocyte count and HIV viral load were 207 cells/μL and > 100,000/mL, respectively (CDC stage C2). On the basis of the TIS classification (Table 1) [17], he was classified as T0I0S0. Antiretroviral therapy (i.e., emtricitabine/tenofovir + darunavir 800 mg/Ritonavir) as well as sulfamethoxazole/trimethoprim were immediately prescribed; after five months his CD4 lymphocyte counts increased (i.e., CD4 = 283 cells/μL) and the level of viral load decreased gradually (i.e., undetectable).

After 15 months since KS diagnosis the patient is alive and KS-free with a CD4 cell count of 342 cells/μL.

3. Discussion

KS is an important opportunistic disease, which frequently occurs in HIV-positive patients characterized by a severe immunodeficiency. The KS incidence in the general population is 1 case per 100,000 inhabitants [18], whereas it is 1 per 20 inhabitants in the HIV-infected population [18]. HHV-8 is the etiological agent associated with all described KS subtypes; the prevalence of the infection is around 20–30% in Europe [18].

The AIDS-related KS lesions, affecting the skin of the upper trunk and face [2, 3], and the mucosa of the oral...
cavity [19], often progress rapidly to plaques and nodules. The oropharyngeal KS and, in particular, isolated KS of the tonsil are extremely rare and only a few cases were described in literature [13, 15, 16]. Raikundalia described the first case of KS located in the upper pole of the left tonsil in a female aged 38. She presented another subcutaneous lesion on her face and thighs. Oropharyngeal KS was surgically treated [12]. Chetty and Batitang described two KS cases of the tonsil in HIV-positive patients who underwent an excisional biopsy, but subsequently both patients defaulted treatment and were lost to follow-up [13]. Sikora et al. illustrated two KS cases in HIV-negative persons [14]. The first was a 49 years old man with a slow growing right tonsillar mass associated with a mobile right level II node. Fine needle aspiration of the lymphonode and the histology of the tonsil mass allow the diagnosis of a KS. After 3 years from the surgery the patient was disease-free [14]. The second patient described was a 34-year-old male showing a 2 cm sized lesion of the base of the tonsil, without any other lesion. No recurrence after 3 years from the tonsillectomy was recorded. Al-Brahim et al. [15] referred to a patient with membranous glomerulonephritis exposed to immunosuppressive therapy. After 10 months of exposure to the therapy the patient developed a tonsil KS. Saxena et al. illustrated a case of a large bilateral KS of the tonsils and adenoids in a 31-year-old man, surgically treated [16]. One of the most relevant series of KS of the head and neck was described by Yu et al. [20]. Among the 121 patients they described 10 (8.3%) showed lesions in the tonsils. Only 12 patients survived from the disease over two years for an overall survival rate of 9.92% [20].

The therapeutic choice and the following prognosis are extremely variable, depending on the stage and the KS type. The AIDS Clinical Trials Group Oncology Committee published criteria for the evaluation of the epidemic KS [18]. The staging system includes the extent of disease (T), the immune system status (I), and presence of systemic symptoms (S) (Table 1) [17].

This classification includes two group of patients: “Good risk category (T0I0S0)” and “Poor risk category (T1I1S1).” The patient that we described was classified as T0I0S0.

KS can be treated with radiotherapy, chemotherapy, biologic agent as interferon alfa, and surgery: in HIV-positive patients it can be managed with HAART or with a combination of this therapeutic approach.

HAART seems to be indispensable in the treatment of the AIDS-related KS, alone or in combination with systemic or/and local therapy [21]. HAART can prevent the occurrence of KS or can induce regression of KS lesions. Some AIDS patients show clinical recovery and prolonged remission while continuing the therapy. Therefore, HAART should be considered first-line treatment for those patients, though in some cases they may require other concomitant treatments. This therapeutic strategy currently recommended is highly effective favouring the reduction of the HIV viral load, the increase of the CD4 T-lymphocyte count, and the decrease of the occurrence of the HIV-related tumours, such as KS. Campanini et al. in their retrospective study on 470 HIV-positive patients treated with HAART showed a reduction cancer probability (i.e., from 3% to 0%) [22]. Despite those positive effects, adverse clinical events can occur; in particular, the immune reconstitution inflammatory syndrome (IRIS), characterized by an exuberant immune-mediated inflammatory response, can increase the treatment-related morbidity [23]. It can allow the recurrence of previously treated opportunistic infections and/or neoplasm [23].

Radiotherapy is an effective palliative treatment reducing pain, bleeding, and oedema. Cutaneous KS is highly radiosensitive as described by Donato et al. in a group of 38 AIDS-associated KS lesions [24]. They show a complete and partial response of 31 lesions (83.8%) and 6 (16.2%) lesions after RT, respectively [24].

Chemotherapy (CHT) can be local (intralesional injection) or systemic (intravenous). Local CHT, based on bleomycin, cisplatin, and vinblastine, can represent an alternative therapy for limited cutaneous KS with complete or partial response rates (range: 60–92%) [25, 26]. Systemic cytotoxic agents are usually prescribed to patients not responding to HAART and/or with widespread mucocutaneous and visceral disease [27]. Several drugs, such as vincristine, vinblastine, etoposide, bleomycin, docetaxel, and paclitaxel, can be administered [18]. Treatment with paclitaxel is limited to patients with recurrent disease after a first-line CHT [18]. Interferon alfa, showing immunomodulatory, antiviral, and antiangiogenetic actions, can be used alone or in combination with HAART. It can favour a remission of the KS lesions in 20 to 60% of the exposed cases [28, 29]. The probability of a positive outcome can significantly increase in case of a therapy longer than 6 months. Its administration should not be considered in case of progressive or visceral disease.

Patients with clinical progression despite CHT and/or HAART can be currently approached with the so-called “Target Therapy” (i.e., antiangiogenetic agents such as inhibitor of vascular endothelial growth factor (VEGF) and thalidomide, metalloproteinases (MMPs), and cytokine signalling pathway inhibitors) [18]. MMPs are a family of zinc-dependent endopeptidases involved in the destruction of the extra-cellular matrix proteins [30], constitutively over-expressed in KS cells, and facilitate tumour invasion and metastatic
localizations [18, 30]. COL-3 can inhibit the activity, activation, and production of MMPs [18, 30]. IL-12 has showed anti-tumour and antiangiogenic activity, downregulating an active G protein coupled receptor encoded by KSHV [18, 31].

Biopsy of the lesion is deemed mandatory for the histological diagnosis, but in cases of isolated cutaneous and visceral KS surgical excision is recommended in association with HAART, as showed in our review [12, 14, 16].

The patient we managed underwent tonsillecctomy and HAART with complete eradication of the tumours.

4. Conclusion

Isolated KS of the tonsil is very rare and can simulate benign or malignant lesions, such as pyogenic granuloma, carcinomas, and sarcomas. Histological diagnosis, HIV testing and CT scans of the chest and abdomen, and an endoscopy of the upper gastrointestinal tract can be helpful for an appropriate stage of the tumours and, consecutively, to plan a better therapeutic approach.

Consent

Patient gave informed consent.

Conflict of Interests

The authors state they have no conflict of interests.

References

[1] Y. Chang, E. Cesarman, M. S. Pessin et al., “Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma,” Science, vol. 266, no. 5192, pp. 1865–1869, 1994.

[2] J. B. Vaishnani, S. S. Bosamiya, and A. M. Momin, “Kaposi’s sarcoma: a presenting sign of HIV,” Indian Journal of Dermatology, Venereology and Leprology, vol. 76, no. 2, article 215, 2010.

[3] W. C. Tan and L. C. Chan, “Kaposi’s sarcoma: case report and treatment options,” Medical Journal of Malaysia, vol. 66, no. 4, pp. 383–384, 2011.

[4] S. S. Hoskote and V. P. Patel, “Pulmonary kaposi sarcoma in AIDS,” Mayo Clinic Proceedings, vol. 87, no. 10, article e77, 2012.

[5] R. Kibria, U. Siraj, and C. Barde, “Kaposi’s sarcoma of the stomach and duodenum in human immunodeficiency virus infection: endoscopic image of interest,” Digestive Endoscopy, vol. 22, no. 3, pp. 241–242, 2010.

[6] J. Ling, R. Coron, P. Basak, and S. Jesmajian, “Recurrent lower gastrointestinal bleeding due to primary colonic Kaposi’s sarcoma in a patient with AIDS,” International Journal of STD & AIDS, vol. 24, no. 11, pp. 908–911, 2013.

[7] R. A. G. Khanmissa, L. Pantanowitz, and L. Feller, “Oral HIV-associated kaposi sarcoma: a clinical study from the Ga-Rankuwa Area, South Africa,” AIDS Research and Treatment, vol. 2012, Article ID 873171, 9 pages, 2012.

[8] M. Fusetti, A. Eilenstein, R. Palosca, F. Goffredo, and P. Narciso, “A case of Kaposi sarcoma of the pharynx as a primary manifestation of the acquired immunodeficiency syndrome,” Acta Otorhinolaryngologica Italica, vol. 16, no. 2, pp. 129–131, 1996.

[9] F. Çelenk, M. Yilmaz, K. Asal, Ö. Ekinci, and N. Tokgöz, “AIDS-related primary Kaposi sarcoma of the nasopharynx,” Ear, Nose, & Throat Journal, vol. 90, no. 6, pp. 1–4, 2011.

[10] N. F. Schiff, D. J. Annino, P. Woo, and S. M. Shapshay, “Kaposi’s sarcoma of the larynx,” Annals of Otology, Rhinology & Laryngology, vol. 106, no. 7, part 1, pp. 563–567, 1997.

[11] M. E. Wyatt, C. J. Finlayson, and V. Moore-Gillorn, “Kaposi’s sarcoma masquerading as pyogenic granuloma of the nasal mucosa,” The Journal of Laryngology & Otology, vol. 112, no. 3, pp. 280–282, 1998.

[12] K. B. Raikundalia, “Kaposi’s sarcoma of the tonsil,” The Journal of Laryngology & Otology, vol. 87, no. 3, pp. 295–297, 1973.

[13] R. Chetty and S. Batitang, “Kaposi’s sarcoma of the tonsil,” ORL, vol. 60, no. 1, pp. 48–50, 1998.

[14] A. G. Sikora, Y. Shnayder, H. Yee, and M. D. DeLacure, “Oropharyngeal kaposi sarcoma in related persons negative for human immunodeficiency virus,” Annals of Otology, Rhinology and Laryngology, vol. 117, no. 3, pp. 172–176, 2008.

[15] N. Al-Brahim, A. H. Zaki, K. El-Merhi, and M. S. Ahmad, “Tonsillar kaposi sarcoma in a patient with membranous glomerulonephritis on immunosuppressive therapy,” Ear, Nose & Throat Journal, vol. 92, no. 7, pp. E1–E4, 2013.

[16] S. Saxena, J. Curry, and M. Tuluc, “Tonsillar Kaposi’s sarcoma: case report and review of the literature,” International Journal of Oral and Maxillofacial Pathology, vol. 4, no. 1, pp. 76–79, 2013.

[17] S. E. Krown, C. Metroka, and J. C. Wernz, “Kaposi’s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria,” Journal of Clinical Oncology, vol. 7, no. 9, pp. 1201–1207, 1989.

[18] L. La Ferla, M. R. Pinzone, G. Gumnari et al., “Kaposi’s sarcoma in HIV-positive patients: the state of art in the HAART-era,” European Review for Medical and Pharmacological Sciences, vol. 17, no. 17, pp. 2354–2365, 2013.

[19] M. Fatahuzadeh and R. A. Schwartz, “Oral Kaposi’s sarcoma: a review and update,” International Journal of Dermatology, vol. 52, no. 6, pp. 666–672, 2013.

[20] D.-X. Yu, S.-J. Pi, and W.-S. Zhang, “Clinical manifestation of oropharyngeal Kaposi’s sarcoma,” Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, vol. 48, no. 3, pp. 241–243, 2013.

[21] R. J. Sullivan and L. Pantanowitz, “New drug targets in Kaposi sarcoma,” Expert Opinion on Therapeutic Targets, vol. 14, no. 12, pp. 1355–1366, 2010.

[22] A. Camparini, M. Marani, A. Mastroianni, C. Cancelleri, and C. Vicini, “Human immunodeficiency virus infection: personal experience in changes in head and neck manifestations due to recent antiretroviral therapies,” Acta Otorhinolaryngologica Italica, vol. 25, no. 1, pp. 30–35, 2005.

[23] T. K. Naidu, P. K. Ramdial, and S. K. Naidoo, “Highly active antiretroviral therapy-associated flare of oropharyngeal Kaposi sarcoma,” Archives of Otolaryngology—Head and Neck Surgery, vol. 138, no. 8, pp. 762–764, 2012.

[24] V. Donato, R. Guaraccia, J. Dognini et al., “Radiation therapy in the treatment of HIV-related Kaposi’s sarcoma,” Anticancer Research, vol. 33, no. 5, pp. 2153–2157, 2013.

[25] J. B. Epstein, F. Lozada-Nur, W. A. McLeod, and J. Spinelli, “Oral Kaposi’s sarcoma in acquired immunodeficiency syndrome. Review of management and report of the efficacy of intraleisonal vinblastine,” Cancer, vol. 64, no. 12, pp. 2424–2430, 1989.
cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome: a clinical trial to evaluate efficacy and discomfort associated with injection,” *Journal of the American Academy of Dermatology*, vol. 28, no. 1, pp. 61–65, 1993.

[27] K. Antman and Y. Chang, “Kaposi's sarcoma,” *The New England Journal of Medicine*, vol. 342, no. 14, pp. 1027–1038, 2000.

[28] J. E. Groopman, M. S. Gottlieb, J. Goodman et al., “Recombinant alpha-2 interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome,” *Annals of Internal Medicine*, vol. 100, no. 5, pp. 671–676, 1984.

[29] H. C. Lane, J. A. Kovacs, J. Feinberg et al., “Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma,” *The Lancet*, vol. 2, no. 8622, pp. 1218–1222, 1988.

[30] L. Pantanowitz, B. J. Dezube, S. Hernandez-Barrantes, S. R. Tahan, and M. K. Dabbous, “Matrix Metalloproteinases in the progression and regression of Kaposi's sarcoma,” *Journal of Cutaneous Pathology*, vol. 33, no. 12, pp. 793–798, 2006.

[31] R. F. Little, J. M. Pluda, K. M. Wyvill et al., “Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma,” *Blood*, vol. 107, no. 12, pp. 4650–4657, 2006.